XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) - USD ($)
$ in Millions
Apr. 30, 2024
Jan. 31, 2024
Oct. 31, 2023
Apr. 30, 2023
Jan. 31, 2023
Oct. 31, 2022
Liabilities            
Contingent Consideration $ 1 $ 1 $ 1 $ 8 $ 3 $ 67
Fair Value, Measurements, Recurring            
Assets            
Total assets measured at fair value 1,106   1,075      
Liabilities            
Total liabilities measured at fair value 45   39      
Fair Value, Measurements, Recurring | Other Current Assets            
Assets            
Cash equivalents (money market funds) 1,022   994      
Derivative instruments (foreign exchange contracts) 14   19      
Fair Value, Measurements, Recurring | Other assets            
Assets            
Trading securities 40   36      
Other investments 30   26      
Fair Value, Measurements, Recurring | Other accrued liabilities            
Liabilities            
Derivative instruments (foreign exchange contracts) 4   2      
Contingent Consideration 1   1      
Fair Value, Measurements, Recurring | Other long-term liabilities            
Liabilities            
Deferred compensation liability 40   36      
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)            
Assets            
Total assets measured at fair value 1,062   1,030      
Liabilities            
Total liabilities measured at fair value 0   0      
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Current Assets            
Assets            
Cash equivalents (money market funds) 1,022   994      
Derivative instruments (foreign exchange contracts) 0   0      
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other assets            
Assets            
Trading securities 40   36      
Other investments 0   0      
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other accrued liabilities            
Liabilities            
Derivative instruments (foreign exchange contracts) 0   0      
Contingent Consideration 0   0      
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other long-term liabilities            
Liabilities            
Deferred compensation liability 0   0      
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)            
Assets            
Total assets measured at fair value 44   45      
Liabilities            
Total liabilities measured at fair value 44   38      
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other Current Assets            
Assets            
Cash equivalents (money market funds) 0   0      
Derivative instruments (foreign exchange contracts) 14   19      
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other assets            
Assets            
Trading securities 0   0      
Other investments 30   26      
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other accrued liabilities            
Liabilities            
Derivative instruments (foreign exchange contracts) 4   2      
Contingent Consideration 0   0      
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other long-term liabilities            
Liabilities            
Deferred compensation liability 40   36      
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)            
Assets            
Total assets measured at fair value 0   0      
Liabilities            
Total liabilities measured at fair value 1   1      
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other Current Assets            
Assets            
Cash equivalents (money market funds) 0   0      
Derivative instruments (foreign exchange contracts) 0   0      
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other assets            
Assets            
Trading securities 0   0      
Other investments 0   0      
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other accrued liabilities            
Liabilities            
Derivative instruments (foreign exchange contracts) 0   0      
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other accrued liabilities | Resolution Bioscience, Inc.            
Liabilities            
Contingent Consideration 1   1      
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other long-term liabilities            
Liabilities            
Deferred compensation liability $ 0   $ 0